Browsing Tag
KOASTAL-1 Study
1 post
Neumora Therapeutics’ KOASTAL-1 study of navacaprant for MDD falls short on primary endpoint
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company specialising in neuroscience, has announced results from the KOASTAL-1…